MRC2 and prostate neoplasm: The findings of this study provide new insight into the consequences of Endo180 upregulation on prostate tumor cells in contact with osteoblasts [4], positive Endo180 immunostaining of tumor cell foci in metastatic bone lesions [4] and raised levels of soluble Endo180 in the serum of patients with osseous and/or visceral metastases [31].